Core Viewpoint - He Yuan Bio (688765.SH) is expected to report significant losses in 2025, with total profit estimated between -167 million to -143 million yuan, and net profit attributable to shareholders also projected in the same range [1] Financial Performance - The company anticipates a revenue of 45 million to 50 million yuan for 2025, representing a year-on-year increase of 78.46% to 98.29% [1] - After excluding non-recurring gains and losses, the net profit attributable to shareholders is expected to be between -191 million to -162 million yuan [1] Key Factors Influencing Performance - The rapid growth in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) [1] - The production line for the related product, with an annual capacity of 10 tons of recombinant human albumin, is still in the ramp-up phase, with capacity expected to gradually increase [1] - The company continues to maintain high levels of investment in research and development, contributing to the overall loss during the reporting period [1]
禾元生物(688765.SH)：2025年预亏1.43亿元至1.67亿元